Elevation Point Wealth Partners Boosts AbbVie Stake

Institutional investor increases holding in pharmaceutical company by over 35%

Mar. 16, 2026 at 9:19am

Got story updates? Submit your updates here. ›

Elevation Point Wealth Partners LLC, an institutional investor, grew its stake in AbbVie Inc. (NYSE:ABBV) by 35.9% during the third quarter, according to a recent filing with the Securities and Exchange Commission. The firm now owns 32,774 shares of the pharmaceutical company's stock, valued at $7.6 million.

Why it matters

AbbVie is a major pharmaceutical company with a diverse product portfolio spanning immunology, oncology, neuroscience, and other therapeutic areas. Institutional investor activity in the stock can provide insights into market sentiment and expectations around the company's performance.

The details

Elevation Point Wealth Partners increased its AbbVie holdings by purchasing an additional 8,652 shares during the third quarter. The firm's total position in AbbVie is now valued at $7.6 million. Several other hedge funds and institutional investors also made changes to their AbbVie positions during the period.

  • Elevation Point Wealth Partners filed the disclosure of its increased AbbVie stake in the third quarter of 2026.

The players

Elevation Point Wealth Partners LLC

An institutional investor that manages a portfolio of equity and fixed-income investments.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across multiple therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

Elevation Point Wealth Partners' increased stake in AbbVie suggests the institutional investor sees value and growth potential in the pharmaceutical company's diversified product portfolio and pipeline. This activity aligns with broader market sentiment, as AbbVie is generally viewed favorably by Wall Street analysts.